Post-earnings recap
Reported
Thu, Nov 12, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
IDEAYA Biosciences reported a larger-than-expected loss per share, which contributed to a 1.46% decline in stock price following the earnings release. The lack of revenue figures and guidance may raise concerns among investors about the company's financial health and future performance. Overall, the results indicate that the company is still navigating challenges in its operations.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.17 | N/A | -112.65% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced this quarter, particularly in terms of financial performance. They emphasized their commitment to ongoing clinical development.
Management did not provide specific revenue guidance for the upcoming quarter.
The focus remains on advancing clinical programs despite the EPS miss.